⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
URGN News
UroGen Pharma Ltd. Ordinary Shares
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
globenewswire.com
URGN
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
globenewswire.com
URGN
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
globenewswire.com
URGN
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
globenewswire.com
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
URGN
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
URGN
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
globenewswire.com
URGN
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
globenewswire.com
URGN
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
globenewswire.com
URGN